MedPath

Open-Label Study of ARD-0403 in Testosterone Deficient Men

Phase 3
Completed
Conditions
Hypogonadism
Registration Number
NCT00448955
Lead Sponsor
Ardana Bioscience Ltd
Brief Summary

Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient wellbeing. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
150
Inclusion Criteria
  • Testosterone deficiency
Exclusion Criteria
  • Previous treatment with testosterone replacement therapy within 4 weeks
  • Moderate-severe benign prostatic hypertrophy, or prostatic cancer
  • Haematocrit >50%

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Pharmacokinetic
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability

Trial Locations

Locations (12)

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

Medical Affiliated Research Center, Inc

🇺🇸

Huntsville, Alabama, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Stanford University

🇺🇸

Stanford, California, United States

Los Angeles Biomedical Research Institute at Harbor-UCLA

🇺🇸

Torrance, California, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Michael E. Debakey VAMC

🇺🇸

Houston, Texas, United States

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

VA Puget Sound Health Care System

🇺🇸

Seattle, Washington, United States

Johns Hopkins University

🇺🇸

Baltimore, Maryland, United States

dgd Research

🇺🇸

San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath